ECLS in Pediatric Cardiac Patients by Matteo Di Nardo et al.
October 2016 | Volume 4 | Article 1091
Review
published: 07 October 2016
doi: 10.3389/fped.2016.00109
Frontiers in Pediatrics | www.frontiersin.org
Edited by: 
Tara Karamlou, 
University of California 
San Francisco, USA
Reviewed by: 
Federico Gutierrez-Larraya, 
Hospital Universitario La Paz, Spain 
Yasuhiro Fujii, 
Okayama University, Japan
*Correspondence:
Matteo Di Nardo 
matteo.dinardo@opbg.net
Specialty section: 
This article was submitted 
to Pediatric Cardiology, 
a section of the journal 
Frontiers in Pediatrics
Received: 23 May 2016
Accepted: 22 September 2016
Published: 07 October 2016
Citation: 
Di Nardo M, MacLaren G, Marano M, 
Cecchetti C, Bernaschi P and 
Amodeo A (2016) ECLS in Pediatric 
Cardiac Patients. 
Front. Pediatr. 4:109. 
doi: 10.3389/fped.2016.00109
eCLS in Pediatric Cardiac Patients
Matteo Di Nardo1*, Graeme MacLaren2,3, Marco Marano1, Corrado Cecchetti1, 
Paola Bernaschi4 and Antonio Amodeo5
1 Pediatric Intensive Care Unit, Children’s Hospital Bambino Gesù, Rome, Italy, 2 Cardiothoracic Intensive Care Unit, National 
University Health System, Singapore, 3 Paediatric Intensive Care Unit, Department of Paediatrics, The Royal Children’s Hospital, 
University of Melbourne, Parkville, VIC, Australia, 4 Microbiology Unit, Children’s Hospital Bambino Gesù, Rome, Italy, 5 ECMO 
and VAD Unit, Children’s Hospital Bambino Gesù, Rome, Italy
Extracorporeal life support (ECLS) is an important device in the management of children 
with severe refractory cardiac and or pulmonary failure. Actually, two forms of ECLS are 
available for neonates and children: extracorporeal membrane oxygenation (ECMO) and 
use of a ventricular assist device (VAD). Both these techniques have their own advan-
tages and disadvantages. The intra-aortic balloon pump is another ECLS device that 
has been successfully used in larger children, adolescents, and adults, but has found 
limited applicability in smaller children. In this review, we will present the “state of art” of 
ECMO in neonate and children with heart failure. ECMO is commonly used in a variety of 
settings to provide support to critically ill patients with cardiac disease. However, a strict 
selection of patients and timing of intervention should be performed to avoid the increase 
in mortality and morbidity of these patients. Therefore, every attempt should be done to 
start ECLS “urgently” rather than “emergently,” before the presence of dysfunction of 
end organs or circulatory collapse. Even though exciting progress is being made in the 
development of VADs for long-term mechanical support in children, ECMO remains the 
mainstay of mechanical circulatory support in children with complex anatomy, particularly 
those needing rapid resuscitation and those with a functionally univentricular circulation. 
With the increase in familiarity with ECMO, new indications have been added, such as 
extracorporeal cardiopulmonary resuscitation (ECPR). The literature supporting ECPR 
is increasing in children. Reasonable survival rates have been achieved after initiation 
of support during active compressions of the chest following in-hospital cardiac arrest. 
Contraindications to ECLS have reduced in the last 5 years and many centers support 
patients with functionally univentricular circulations. Improved results have been recently 
achieved in this complex subset of patients.
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iNTRODUCTiON
Mechanical circulatory support is an important tool in the management of children with cardiac 
failure. Two major forms of mechanical circulatory support are currently available in neonates and 
children: extracorporeal life support (ECLS, also known as extracorporeal membrane oxygenation or 
ECMO) and ventricular assist device (VAD). Each of these devices has advantages and disadvantages. 
Another device that has been used in older children is the intra-aortic balloon pump. As mechani-
cal circulatory support in children has evolved, the indications have expanded and outcomes have 
improved.
FiGURe 1 | Annual neo/ped eCMO runs. (International Summary 2016. Courtesy of P. Rycus from the ELSO Registry).
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Survival for children with heart failure on ECLS has progres-
sively improved over the past two decades, and this is occurring 
despite placing more complex patients on support, including a 
significant proportion with single-ventricle physiology, end-stage 
heart failure or in cardiac arrest (1). Survival to hospital discharge 
after cardiac ECLS is generally between 40 and 50% (2, 3). 
However, it is important to consider not only crude, short-term 
survival but also the quality of survival in terms of functional 
outcome. Unfortunately, data regarding quality of life after car-
diac ECLS are generally limited to single center experiences and 
insufficient research has taken place to study this in greater detail. 
Data from the Extracorporeal Life Support Organization (ELSO) 
Registry indicate that ECLS was used to provide cardiac support 
for over 1,200 pediatric patients in 2016 (Figure 1) (1). Important 
potential determinants of outcome after ECLS for cardiac disease 
can be broadly categorized according to indication (the underly-
ing disease); timing of ECLS initiation; center-specific strategies 
(cannulation), as well as comorbidities in individual patients 
(Figure 2).
The purpose of this review article is to outline current manage-
ment strategies in the application of ECLS to children with heart 
disease, review recent evidence about the effect of these strategies, 
and provide an overview of the topic for clinicians.
iNDiCATiONS FOR CARDiAC eCLS
Indications and contraindications for ECLS in neonates and 
children with cardiovascular disease have evolved during the past 
45 years. Advances in ECLS circuit design and greater recognition 
that ECLS is beneficial for indications beyond early postoperative 
support have resulted in steady growth in the number of pediatric 
patients who receive cardiac ECLS. The indications for ECLS can 
be divided into two groups: those involving cardiac surgery and 
not. The indications related to cardiac surgery include preopera-
tive stabilization, failure to wean postcardiotomy, low cardiac out-
put syndrome in the postoperative period, and cardiac arrest. The 
indications in the absence of cardiac surgery are cardiac arrest, 
myocarditis and cardiomyopathy, pulmonary hypertension, 
FiGURe 2 | Cardiac Runs by diagnosis: % of survival on eCMO. Avg, average.
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intractable arrhythmias, and other forms of shock, such as sepsis 
or Kawasaki’s Disease (4).
Preoperative Stabilization
Extracorporeal life support is required in a small subset of neonates 
prior to initial surgical repair or palliation. The primary goals of 
ECLS support are to optimize the hemodynamic state, maximize 
oxygen delivery, and prevent or mitigate any multiorgan failure 
prior to surgical repair. The use of ECLS in this setting may 
improve the candidacy of some patients with complex surgical 
repair. Hypoxemia and cardiogenic shock in patients with arterial 
transposition or hypoplastic left heart syndrome with inadequate 
atrial shunting have been the most common indications for preop-
erative ECLS support (4). Neonates with late presentation arterial 
transposition and pulmonary hypertension represent a high-risk 
population. ECLS may be necessary to provide cardiopulmonary 
stabilization until pulmonary vascular resistance declines and 
the arterial switch operation can be safely performed (5–7). 
Neonates with absent pulmonary valve syndrome who present 
with refractory respiratory failure despite aggressive mechanical 
ventilation may also be candidates for preoperative stabilization, 
although the associated respiratory complications are often fatal 
in the long-term despite this (8). Similarly, patients with severe 
Ebstein’s anomaly and functional pulmonary atresia who present 
with low cardiac output secondary to a circular shunt, intractable 
dysrhythmias, or cyanosis secondary to inadequate pulmonary 
blood flow may benefit from VA ECLS stabilization during the 
period of transitional circulation until pulmonary vascular 
resistance declines and a stable source of pulmonary blood flow 
is established (9, 10).
Perioperative Support
The role of ECMO to provide postcardiotomy support for chil-
dren with severe cardiac dysfunction after surgery for congenital 
heart disease (CHD) is well established. Mechanical circulatory 
support may be required in the postoperative period, either due 
to inability to wean from bypass or because of a progressive 
low cardiac output syndrome. Patients who are subjected to 
prolonged periods of cardiopulmonary bypass can experience 
severe postoperative myocardial dysfunction that may prevent 
successful separation from cardiopulmonary bypass. Children 
who have preexisting ventricular dysfunction or certain 
structural cardiac abnormalities [such as hypoplastic left heart 
syndrome (HLHS)] may be at greatest risk. Once correctable 
residual anatomic lesions have been excluded, ECLS may be 
used to provide short-term cardiopulmonary support. In most 
cases, the cannulation strategy utilized for cardiopulmonary 
bypass is adequate during and after the transition to ECMO. 
Veno-arterial ECMO is the most commonly used modality in 
neonatal and pediatric cardiac patients during the periopera-
tive period although veno-venous ECMO may be used in select 
circumstances, such as intraoperative pulmonary hemorrhage, 
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which can occasionally occur in lesions, such as Tetralogy of 
Fallot and its related variants.
There is no consensus regarding the optimal timing for ECMO 
initiation in the perioperative period. Some reports suggest the 
absence of a clear relationship between timing of ECLS initiation 
and clinical outcome, whereas others describe improved survival 
in patients who receive early ECLS support, including those who 
transition to ECLS in the operating room, compared to those who 
receive support later in the postoperative period (11–16). ECMO 
is used to provide perioperative support in 10% patients with 
HLHS who undergo the Norwood operation (17). Irrespective 
of the patient population, it is important to recognize that earlier 
initiation of ECLS facilitates unloading of vulnerable myocar-
dium, prevention or reduction of acidosis, and reduced risk of 
cardiovascular collapse.
eCLS Beyond the Perioperative Period
Although the vast majority of neonatal and pediatric cardiac 
ECLS occurs in patients with structural CHD who are undergo-
ing surgical repair or palliation, patients without structural heart 
disease may require ECLS to manage severe heart failure.
Children with acute fulminant myocarditis can benefit 
from mechanical circulatory support as a bridge to recovery. 
Cardiomyopathy (8.3%) and myocarditis (4.5%) are the most 
common non-structural etiologies of heart failure in neonates 
and children reported to the ELSO registry (1). Overall survival 
in this patient population is ~67% and appears to be greatest in 
older pediatric patients and in those without signs of end-organ 
injury, such as renal failure (18, 19). Data suggest that ECMO 
may be necessary in ~50% of patients who present with myo-
carditis (20). Low cardiac output state and arrhythmias are the 
primary indications for ECLS in the majority of these patients. 
Rhythm-related low cardiac output states may result from tach-
ycardia-induced cardiomyopathy or the myocardial depressant 
effects of anti-arrhythmic medications (21). ECLS is also equal 
occasionally used to provide support for patients who experience 
cardiovascular collapse due to accidental or intentional poisoning 
(22) and for patients who experience life-threatening pulmonary 
hypertensive crises (23). The use of mechanical cardiac support 
in the management of end-stage heart failure has dramatically 
evolved during the past two decades. Short-term extracorporeal 
devices and durable implantable VADs are now standard heart 
failure therapies in adults and children. Technologic advances 
in highly efficient implantable centrifugal and axial flow pumps 
have proven difficult to miniaturize for use in infants and neo-
nates. Consequentially, ECLS remains an important component 
of mechanical heart failure therapy in some patient populations.
Extracorporeal life support can be used as a bridge to trans-
plantation in children with irreversible myocardial dysfunction 
(24–26). This includes patients with dilated cardiomyopathy, 
restrictive cardiomyopathy, and end-stage congenital cardiac 
disease. However, data from a large, propensity score-matched 
study showed that overall survival rates are significantly higher 
in pediatric patients who are bridged to transplantation with a 
VAD than ECLS (27). Even if VAD appears to be a superior form 
of bridge to transplantation in older children and in children with 
non-structural heart disease, VAD technology in small children 
has higher complication rates than in older children and adults, 
and outcomes can be disappointing (28). In one study, 29% of 
children experienced a stroke and 97% experienced some form of 
serious adverse event during support (28). There is general con-
sensus that ECLS is useful as a bridge-to-decision and as a bridge-
to-bridge (bridge-to-VAD) (29). When used in the setting of 
acute hemodynamic decompensation, including extracorporeal 
cardiopulmonary resuscitation (ECPR), ECLS is readily available 
and considerably less expensive compared to VAD. In most cases, 
the degree of myocardial recovery, if any, is unknown at time 
of initiation therefore ECLS is preferred. During this period of 
clinical uncertainty, ECLS is useful as a bridge to decision about 
transplant candidacy because neurologic tests and organs (liver 
and kidney) recovery can be evaluated.
Extracorporeal life support can also be used after heart trans-
plantation. Indications for support in this setting include failure 
to separate from cardiopulmonary bypass and progressive low 
cardiac output syndrome in the immediate postoperative period, 
along with circulatory collapse due to rejection or graft vasculopa-
thy later in the course (30, 31). Overall survival is approximately 
50% in this population (1) and neonates and infant seem to be 
at greater risk for death than older children. The use of ECLS 
as a bridge to recovery for patients who experience severe acute 
rejection remote from transplantation is less successful and many 
patients will ultimately require re-transplantation (32). Right 
heart failure and/or pulmonary hypertension are often respon-
sible for the inability to separate from cardiopulmonary bypass 
and ECLS can be very useful in managing this postoperatively.
CONTRAiNDiCATiONS FOR CARDiAC 
eCLS
The list of contraindications to ECLS in children with heart dis-
ease is shrinking over time. Absolute contraindications include 
lethal chromosomal abnormalities, severe irreversible brain 
injury, and extremely low gestational age and weight (<32 weeks 
gestation or <1.5 kg). Relative contraindications include moder-
ate intra-ventricular hemorrhage, gestational age <34  weeks, 
weight <2.0  kg, and certain high-risk congenital heart lesions, 
such as those that co-exist with congenital diaphragmatic hernia. 
Data from the ELSO registry indicate that the overall survival rate 
for premature infants (<37 weeks gestation) who receive cardiac 
ECLS is 31%, compared to 41% survival in term infants (1). 
Similarly, the reported survival rate following ECPR approaches 
30% in preterm babies and is as low as 21% in neonates <34 weeks 
gestational age (33). Weight <2  kg has historically also been a 
relative contraindication to ECLS but survival a rate of 10% has 
been reported in neonates with hypoplastic left heart syndrome 
weighing <2.5 kg when placed on ECLS (34) and a survival rate 
of 33% has been reported for infants weighing <3 kg at time of 
cardiac ECLS support (35).
NeONATAL AND PeDiATRiC 
CANNULATiON
The approach to cannulation should be flexible and based on 
the underlying need for ECMO. Transthoracic cannulation of 
5Di Nardo et al. ECLS and Pediatric Heart Failure
Frontiers in Pediatrics | www.frontiersin.org October 2016 | Volume 4 | Article 109
the right atrial appendage and the ascending aorta can be used 
in cases of failure to wean from cardiopulmonary bypass. In the 
immediate postoperative period, reopening the sternal wound 
and direct cardiac cannulation provides the most expeditious 
route to institute support, especially in patients who suffer cardiac 
arrest. Adequate venous drainage and excellent arterial perfusion 
should be assured by chest cannulation, providing the cannulas 
are placed properly; however, severe hemorrhage and mediastini-
tis remain disadvantages of chest cannulation, making peripheral 
cannulation preferable in most other settings.
Cannulation of the right internal jugular vein and the com-
mon carotid artery provides excellent venous drainage and 
perfusion and is the preferred cannulation site in neonates and 
children below 15 kg. Cannulation of the femoral vessels provides 
adequate venous drainage and perfusion for larger children. A 
second venous drainage cannula placed in the right internal jugu-
lar vein may be added if venous drainage is inadequate through 
the femoral route. To avoid ischemia of the lower extremities, a 
perfusion cannula in the distal femoral artery is placed by many 
groups. Venous congestion of the lower extremities is less fre-
quent and usually does not require treatment.
In cases of severe heart dysfunction, inadequate decompres-
sion of the left-sided cardiac chambers during ECLS may be 
seen. A number of strategies can be implemented to address this. 
Left-sided distension may be managed by increasing ECLS flow 
to empty the right heart, minimizing pulmonary blood flow, and 
decreasing pulmonary venous return to the left heart. However, 
this increases the afterload to the systemic ventricle, which may 
cause the aortic valve to close, in turn risking thrombus forma-
tion in the ventricle as well as hemorrhagic pulmonary edema if 
the end-diastolic pressure rises too high. In cases of persistent 
distension of the systemic ventricle, a balloon atrial septostomy 
can be performed in the cardiac catheterization laboratory. If this 
is not technically possible, additional surgical options include 
changing to central cannulation, with or without biatrial cannula-
tion, inserting an atrial vent via a pulmonary vein, or inserting an 
apical ventricular vent (36). These vents are incorporated into the 
ECLS circuit by means of a Y-connector.
SPeCiAL eCLS iNDiCATiONS
intractable Arrhythmias with 
Hemodynamic Compromise and 
Procedural Support
In selected patients with malignant tachyarrhythmias or bradyar-
rhythmias, ECLS may be necessary to mitigate cardiogenic shock 
while medical therapy is being optimized or in order to safely 
facilitate catheter ablation or pacemaker insertion. Generally, 
patients with severe myocarditis or dilated cardiomyopathy are 
supported with ECLS to manage severe arrhythmias. Severe 
arrhythmias can also present after cardiac surgery or in lesions, 
such as Ebstein’s malformation (37–39). Catheter-based inter-
ventional and diagnostic procedures can be safely performed 
on patients receiving ECLS support (40). The most common 
indications for cardiac catheterization on ECLS are assessment 
of operative results and percutaneous left heart decompression. 
Early detection and correction of residual cardiac lesions is 
associated with improved survival so the use of catheter-based 
diagnostic procedures should be considered when non-invasive 
diagnostic studies fail to identify a reason for inability to separate 
from ECLS (41, 42). ECLS has also been considered as a safe 
alternative to cardiopulmonary bypass during complex airway 
surgery and repair of pulmonary artery sling (43).
extracorporeal Cardiopulmonary 
Resuscitation
As the experience with ECLS has grown, new indications have 
evolved, including emergent resuscitation. del Nido and col-
leagues (44) initially described the use of rapid resuscitation with 
ECLS after cardiopulmonary arrest. In a retrospective study, all 
patients with CPR duration of less than 15 min survived, while 
only just over half survived when those times were greater than 
42 min (45). Clinical outcomes tend to be better in children who 
require ECPR for underlying cardiac disease than those who 
have cardiac arrest without structural heart disease (46). This 
may be because children with structural heart disease who suffer 
cardiac arrest are often monitored in an intensive care setting 
and have adequate vascular access. These patients tend to be 
younger, less likely to have preexisting organ dysfunction, and 
more likely to experience ventricular dysrhythmias than asystole 
prior to cardiac arrest (47, 48). Potential benefits of ECPR in these 
patients include improved myocardial oxygen delivery, reduced 
myocardial workload, reduced vasopressor and inotropic therapy, 
reduced pulmonary barotrauma and intrathoracic pressure, 
improved end-organ perfusion and oxygen delivery, reversal of 
acidosis, and targeted temperature control. Current resuscita-
tion guidelines from the International Liaison Committee on 
Resuscitation support the use of ECPR in pediatric patients with 
a cardiac diagnosis who experience in-hospital cardiac arrest in a 
center with ECLS expertise (49).
eCLS in Patients with Functionally 
Univentricular Circulation
Many centers previously considered a functionally univen-
tricular circulation a contraindication to ECLS. However, this 
view is anachronistic and outcomes can be satisfactory in many 
instances. In addition to the same indications for ECLS as in 
children with biventricular hearts, shunt thrombosis may also 
require ECLS and is associated with excellent outcomes when the 
thrombosis is swiftly identified and corrected. However, while 
the indications are similar, the cannulation strategies require 
careful planning.
Management of the infant with single ventricular physiology 
and a systemic-pulmonary shunt can be safely achieved by leav-
ing the shunt patent and increasing the net ECLS circuit flow to 
compensate for the pulmonary run-off (Figure 3). Generally a 
150–200 ml/kg/min of blood flow may be required. This man-
agement associated with better outcomes than occluding the 
shunt, which was often done historically an attempt to reduce 
pulmonary edema from excessive pulmonary blood flow (50, 
51). In situations where the lungs are normal, it is possible also 
to remove the oxygenator and continue ECLS as a centrifugal 
VAD. Sherwin and colleagues (14) reported the outcomes of a 
FiGURe 3 | eCLS in single-ventricle physiology: first stage support with Blalock–Taussig (BT) shunt using eCMO or vAD according to patient’s gas 
exchange. Technical aspects: to better support first stage hypoplastic left heart syndrome the BT shunt should be narrowed to avoid pulmonary overflow. SVC, 
superior vena cava; IVC, inferior vena cava; PV, pulomanry veins; TV, tricuspidal valve; RV, right ventricle; LPA, left pulmonary artery; RPA, right pulmonary artery; 
Ao, aorta (courtesy of Dr. Massimo Griselli).
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large multicenter cohort of neonates requiring ECMO after stage 
1 palliation for HLHS. These authors used the data of the ELSO 
Registry from 2000 to 2009 to evaluate the survival to hospital 
discharge in this subset of patients. Among 738 neonates, the 
survival was 31%. Thus, the mortality for neonates with HLHS 
supported with ECMO was high compared with those with other 
defects (14). This study showed how longer ventilation time 
before ECMO, longer support duration and ECMO complica-
tions, such as renal failure, myocardial stun, inotrope require-
ment, metabolic acidosis, and neurologic injury, increase the 
mortality of these patients.
There is limited experience with mechanical support in 
patients with cavo-pulmonary connections and outcomes are not 
so good as for other indications, most likely due to a combination 
of previous surgery, complex physiology, difficult cannulation 
approach, the need to address venous drainage from both supe-
rior and inferior vena cava and the inadequacy of conventional 
cardiopulmonary resuscitation (CPR) to provide sufficient blood 
flow if these children suffer of cardiac arrest (52–54).
Patients who have undergone Glenn procedure (Figure  4) 
have a unique cardiopulmonary-cerebral physiology that limit 
the success of CPR and ECMO. Jolley and colleagues (52) 
analyzed the data of the ELSO Registry from 1999 to 2012 to 
evaluate the survival to hospital discharge in children with Glenn 
physiology. A total of 103 infants were identified and survival 
to hospital discharge was 41%. Survival is high compared with 
the outcome data from similar ELSO Registry analysis follow-
ing stage I palliation for HLHS (31%) and Fontan (35%). The 
unique surgical anatomy and physiology of Glenn procedure 
may explain the limited efficacy of standard medical manage-
ment and resuscitation. The approach to ECLS in patients who 
have the Glenn procedure is particular. In these patients, there 
are two separated source of venous return to the single ventricle: 
the IVC carrying desaturated blood directly to the heart and 
the superior vena cava (SVC), which indirectly returns oxygen-
ated blood, via the lungs, to the common atrium. An inability 
to maintain adequate venous drainage and systemic perfusion 
may contribute to worse outcomes. When dual venous cannulae 
are placed (femoral/atrial and SCV), Booth and colleagues (55) 
recommend placing the SVC cannula first to address cerebral 
venous congestion. In multivariate analysis (52), the need for 
inotropic support before ECMO, longer duration of ECMO and 
the development of renal failure remained statistically significant 
in increasing mortality. Combined cardiopulmonary indication 
for ECMO was also statistically significant when analyzing for 
mortality, suggesting that the combination of both respiratory 
and cardiac disease in this subset of patients is difficult to man-
age with ECMO. These indicators of poor prognosis could aid 
in clinical management decisions regarding the utility and/or 
timing of initiation of ECMO.
FiGURe 5 | eCLS in single-ventricle physiology: third stage support 
(Fontan Physiology) using eCMO or vAD according to patient’s gas 
exchange (courtesy of Dr. Massimo Griselli).
FiGURe 4 | eCLS in single-ventricle physiology: second stage support (Glenn Physiology) using eCMO or vAD according to patient’s gas exchange. 
Technical consideration: the inflow cannula can be atrial or ventricular (courtesy of Dr. Massimo Griselli).
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Adequate flow drainage is complicated also in Fontan patients 
(53, 54). Due to the difficulty of transthoracic cannulation in 
this population, peripheral cannulation may be used, resulting 
in inadequate decompression of either the superior or inferior 
vena cava unless cannulation of both the femoral and internal 
jugular veins is performed. The trade-off is that with adequate 
cavo-pulmonary decompression, preload to the single ventricle 
is decreased due to reduced blood flow through the lungs. The 
single ventricle is often failing, and imposing high afterload 
from external arterial flow can inhibit ventricular ejection of 
any blood traversing the pulmonary bed (Figure  5). Together 
these factors can create a state where most of the cardiac output 
and oxygen delivery must be provided by the ECMO flow, with 
little or no contribution from ventricular ejection; however, fully 
supportive flows often cannot be achieved with peripheral can-
nulation alone. In these patients with Fontan physiology, CPR is 
generally ineffective and despite the challenges associated with 
ECMO, elective cannulation and initiation of ECMO before 
cardiac arrest in patients with potentially reversible causes of 
a failing Fontan has been used (53, 55). In the largest series 
of 230 patients, 35% of all patients with Fontan procedure on 
ECMO survived to hospital discharge. In this subset, CPR prior 
to ECMO initiation was associated with non-survival. Mortality 
also was associated with the duration of ECMO support and 
the development of renal failure or neurological complications 
(54, 55).
8Di Nardo et al. ECLS and Pediatric Heart Failure
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